CN102548578A - 疫苗 - Google Patents
疫苗 Download PDFInfo
- Publication number
- CN102548578A CN102548578A CN2010800374300A CN201080037430A CN102548578A CN 102548578 A CN102548578 A CN 102548578A CN 2010800374300 A CN2010800374300 A CN 2010800374300A CN 201080037430 A CN201080037430 A CN 201080037430A CN 102548578 A CN102548578 A CN 102548578A
- Authority
- CN
- China
- Prior art keywords
- immunogenic composition
- described immunogenic
- protein polypeptide
- polypeptide
- rsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (63)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21995809P | 2009-06-24 | 2009-06-24 | |
US61/219,958 | 2009-06-24 | ||
PCT/EP2010/059006 WO2010149743A2 (en) | 2009-06-24 | 2010-06-24 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102548578A true CN102548578A (zh) | 2012-07-04 |
Family
ID=42797417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800374300A Pending CN102548578A (zh) | 2009-06-24 | 2010-06-24 | 疫苗 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8889146B2 (zh) |
EP (1) | EP2445527A2 (zh) |
JP (1) | JP5796011B2 (zh) |
KR (1) | KR20120093811A (zh) |
CN (1) | CN102548578A (zh) |
AU (1) | AU2010264686A1 (zh) |
CA (1) | CA2766205A1 (zh) |
EA (1) | EA201270062A1 (zh) |
IL (1) | IL217008A0 (zh) |
MX (1) | MX2012000036A (zh) |
SG (1) | SG176807A1 (zh) |
WO (1) | WO2010149743A2 (zh) |
ZA (1) | ZA201109164B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102743750A (zh) * | 2012-07-09 | 2012-10-24 | 江苏省农业科学院 | 一种复方免疫增强剂、禽用疫苗及其制备方法 |
CN105188748A (zh) * | 2013-04-08 | 2015-12-23 | 米迪缪尼有限公司 | 疫苗组合物及使用方法 |
CN105693829A (zh) * | 2016-04-14 | 2016-06-22 | 青岛易邦生物工程有限公司 | 一种b型禽偏肺病毒f蛋白 |
CN106119287A (zh) * | 2016-08-29 | 2016-11-16 | 广东华南联合疫苗开发院有限公司 | 一种表达呼吸道合胞病毒f蛋白的重组载体及方法 |
WO2018095330A1 (zh) * | 2016-11-22 | 2018-05-31 | 黄立民 | 重组rsv抗原 |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4219566A3 (en) * | 2007-12-24 | 2023-09-06 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
BRPI1015917A2 (pt) | 2009-06-24 | 2019-08-27 | Glaxosmithkline Biologicals Sa | antígenos de rsv recombinantes. |
WO2011008974A2 (en) | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
PT2667892T (pt) | 2011-01-26 | 2019-06-07 | Glaxosmithkline Biologicals Sa | Regime de imunização contra o vsr |
CA2825722A1 (en) * | 2011-01-28 | 2012-08-02 | Medimmune, Llc | Expression of soluble viral fusion glycoproteins in mammalian cells |
EP2707385B1 (en) | 2011-05-13 | 2017-09-20 | GlaxoSmithKline Biologicals SA | Pre-fusion rsv f antigens |
US9463236B2 (en) | 2011-08-29 | 2016-10-11 | Tokushima University | RSV mucosal vaccine |
EP4176871A1 (en) | 2011-10-03 | 2023-05-10 | Canqura Oncology Ab | Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds |
CN104350069B (zh) * | 2012-03-20 | 2017-12-01 | 胡默波斯生物医学公司 | 中和rsv、mpv和pvm的抗体和其应用 |
EA039682B1 (ru) * | 2012-06-04 | 2022-02-28 | Хумабс Биомед Са | Антитела, нейтрализующие rsv, mpv и pvm, и их применения |
KR20220119527A (ko) | 2012-08-01 | 2022-08-29 | 버베리안 노딕 에이/에스 | 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신 |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
CA2879939A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Novel method |
EP2922570A1 (en) * | 2012-11-20 | 2015-09-30 | GlaxoSmithKline Biologicals SA | Rsv f prefusion trimers |
KR102450375B1 (ko) * | 2013-03-13 | 2022-10-04 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 선융합(prefusion) RSV F 단백질 및 이의 용도 |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
US9060975B2 (en) * | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
RS58436B1 (sr) | 2013-04-25 | 2019-04-30 | Janssen Vaccines & Prevention Bv | Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi |
KR102313153B1 (ko) | 2013-06-17 | 2021-10-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 rsv f 폴리펩타이드 |
CN105555304A (zh) | 2013-08-05 | 2016-05-04 | 葛兰素史密丝克莱恩生物有限公司 | 联合免疫原性组合物 |
US9388430B2 (en) * | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
WO2016103238A1 (en) | 2014-12-24 | 2016-06-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant metapneumovirus f proteins and their use |
WO2016144675A1 (en) * | 2015-03-06 | 2016-09-15 | Medimmune, Llc | Vaccine dose and use thereof |
BR112017028449A2 (pt) | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | polipeptídeos rsv f pré-fusão solúveis estabilizados |
PL3319633T3 (pl) | 2015-07-07 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Szczepionka przeciwko rsv |
DK3718565T3 (da) | 2015-10-22 | 2022-06-20 | Modernatx Inc | Vacciner mod respiratorisk virus |
JP6817307B2 (ja) | 2015-12-23 | 2021-01-20 | ファイザー・インク | Rsv fタンパク質突然変異体 |
KR20220041966A (ko) | 2016-04-05 | 2022-04-01 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 용해성 융합-전 rsv f 단백질 |
MA43762A (fr) | 2016-04-05 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Vaccin contre le rsv |
WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
EA039124B1 (ru) | 2016-05-30 | 2021-12-08 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизированные f-белки rsv до слияния |
US11078239B2 (en) * | 2016-10-25 | 2021-08-03 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Prefusion PIV F immunogens and their use |
EP3551193A4 (en) * | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
US20200030432A1 (en) | 2017-03-17 | 2020-01-30 | Modernatx, Inc. | Zoonotic disease rna vaccines |
EP3624845A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
US11306292B2 (en) | 2017-05-15 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
JP2020519663A (ja) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Rsv感染に対する防御免疫を誘導するための方法及び組成物 |
BR112020004143A2 (pt) | 2017-09-15 | 2020-09-01 | Janssen Vaccines & Prevention B.V. | método para a indução segura de imunidade contra vírus sincicial respiratório (rsv) |
WO2019063844A1 (en) * | 2017-09-29 | 2019-04-04 | Universiteit Antwerpen | VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS |
WO2019092002A1 (en) * | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
JOP20210106A1 (ar) | 2018-11-13 | 2023-01-30 | Janssen Vaccines And Prevention B V | بروتينات rsv f سابقة الاندماج مستقرة |
JP2022523157A (ja) * | 2019-02-11 | 2022-04-21 | エモリー ユニバーシティー | キメラ型RSVおよびhMPV Fタンパク質、免疫原性組成物、ならびに使用方法 |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
EP4096683A4 (en) * | 2020-01-30 | 2024-04-10 | ModernaTX, Inc. | IMMUNIZATION COMPOSITIONS FOR RESPIRATORY VIRUSES |
TW202233232A (zh) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
KR20230146047A (ko) * | 2021-02-12 | 2023-10-18 | 머크 샤프 앤드 돔 엘엘씨 | 메타뉴모바이러스에 결합하는 항체, 항원성 메타뉴모바이러스 단백질, 및 그의 용도 |
MX2023009738A (es) | 2021-02-19 | 2023-08-30 | Janssen Vaccines & Prevention Bv | Antigenos de rsv fb prefusion estabilizados. |
CA3239461A1 (en) * | 2021-11-30 | 2023-06-08 | Yvonne CHAN | Human metapneumovirus viral vector-based vaccines |
WO2023102373A1 (en) * | 2021-11-30 | 2023-06-08 | Sanofi Pasteur Inc. | Human metapneumovirus vaccines |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993014207A1 (en) * | 1992-01-06 | 1993-07-22 | Connaught Laboratories Limited | Chimeric immunogens |
WO2005027825A2 (en) * | 2003-04-25 | 2005-03-31 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
WO2006038131A2 (en) * | 2004-10-08 | 2006-04-13 | European Molecular Biology Laboratory | Inhibitors of infection |
WO2008114149A2 (en) * | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
WO2009079796A1 (en) * | 2007-12-24 | 2009-07-02 | Id Biomedical Corporation Of Quebec | Recombinant rsv antigens |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US6245549B1 (en) * | 1990-06-28 | 2001-06-12 | Connaught Laboratories Limited | Production of virus and purification of viral envelope proteins for vaccine use |
GB9120221D0 (en) | 1991-09-23 | 1991-11-06 | Smithkline Beecham Biolog | Novel compounds |
KR100278157B1 (ko) | 1992-06-25 | 2001-01-15 | 장 스테판느 | 보조약을 함유하는 백신 조성물 |
AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
RU2154068C2 (ru) | 1993-11-17 | 2000-08-10 | Лаборатуар Ом С.А. | Глюкозаминовые дисахариды, способ их получения, фармацевтическая композиция |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US7208161B1 (en) | 1997-05-23 | 2007-04-24 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
ATE287957T1 (de) | 1997-09-19 | 2005-02-15 | Wyeth Corp | Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
WO1999064301A1 (fr) | 1998-06-08 | 1999-12-16 | Sca Emballage France | Emballage a remise a plat rapide |
CZ302062B6 (cs) | 1998-06-30 | 2010-09-22 | Om Pharma | Derivát acyldipeptidu, zpusob jeho prípravy, meziprodukty pro jeho prípravu a farmaceutický prostredek, který ho obsahuje |
JP2003519084A (ja) | 1998-10-16 | 2003-06-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
AU2002223275A1 (en) | 2000-11-22 | 2002-06-03 | Biota Scientific Management Pty Ltd | A method of expression and agents identified thereby |
DE60233049D1 (de) | 2001-01-26 | 2009-09-03 | Selexis Sa | Matrix-anheftungsregionen und verfahren zu deren verwendung |
DE60238471D1 (de) | 2001-03-09 | 2011-01-13 | Id Biomedical Corp Quebec | Proteosom-liposaccharid-vakzine-adjuvans |
ES2314042T3 (es) | 2001-04-17 | 2009-03-16 | Dainippon Sumitomo Pharma Co., Ltd. | Derivados nuevos de adenina. |
ATE416771T1 (de) | 2001-11-16 | 2008-12-15 | 3M Innovative Properties Co | N-ä4-(4-amino-2-ethyl-1h-imidazoä4,5-cüchinolin 1-yl)butylümethanesulfonamide, diese enthaltende pharmazeutische zusammensetzung und deren verwendung |
DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
AU2003256823B9 (en) * | 2002-07-25 | 2009-01-08 | Medimmune, Llc | Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies |
US7375180B2 (en) | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
US7563449B2 (en) | 2003-04-21 | 2009-07-21 | Pfizer Inc, | Methods for reducing cattle reproductive diseases |
US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
IN2014DN02484A (zh) | 2003-10-24 | 2015-05-15 | Selexis Sa | |
FR2873378A1 (fr) | 2004-07-23 | 2006-01-27 | Pierre Fabre Medicament Sa | Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
US20100261155A1 (en) * | 2007-06-06 | 2010-10-14 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
EP2190470B1 (en) | 2007-08-13 | 2017-12-13 | GlaxoSmithKline Biologicals SA | Vaccines |
BRPI1015917A2 (pt) | 2009-06-24 | 2019-08-27 | Glaxosmithkline Biologicals Sa | antígenos de rsv recombinantes. |
-
2010
- 2010-06-24 EA EA201270062A patent/EA201270062A1/ru unknown
- 2010-06-24 KR KR1020127001752A patent/KR20120093811A/ko not_active Application Discontinuation
- 2010-06-24 CA CA2766205A patent/CA2766205A1/en active Pending
- 2010-06-24 WO PCT/EP2010/059006 patent/WO2010149743A2/en active Application Filing
- 2010-06-24 CN CN2010800374300A patent/CN102548578A/zh active Pending
- 2010-06-24 SG SG2011091881A patent/SG176807A1/en unknown
- 2010-06-24 MX MX2012000036A patent/MX2012000036A/es not_active Application Discontinuation
- 2010-06-24 AU AU2010264686A patent/AU2010264686A1/en not_active Abandoned
- 2010-06-24 EP EP10728203A patent/EP2445527A2/en not_active Withdrawn
- 2010-06-24 US US13/378,402 patent/US8889146B2/en active Active
- 2010-06-24 JP JP2012516745A patent/JP5796011B2/ja active Active
-
2011
- 2011-12-13 ZA ZA2011/09164A patent/ZA201109164B/en unknown
- 2011-12-15 IL IL217008A patent/IL217008A0/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993014207A1 (en) * | 1992-01-06 | 1993-07-22 | Connaught Laboratories Limited | Chimeric immunogens |
WO2005027825A2 (en) * | 2003-04-25 | 2005-03-31 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
CN1813061A (zh) * | 2003-04-25 | 2006-08-02 | 免疫医疗疫苗公司 | 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗 |
WO2006038131A2 (en) * | 2004-10-08 | 2006-04-13 | European Molecular Biology Laboratory | Inhibitors of infection |
WO2008114149A2 (en) * | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
WO2009079796A1 (en) * | 2007-12-24 | 2009-07-02 | Id Biomedical Corporation Of Quebec | Recombinant rsv antigens |
Non-Patent Citations (8)
Title |
---|
ASUNCIO´N MEJı´AS ET AL: "New approaches to reduce the burden of RSV infection", 《DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES》, vol. 3, no. 2, 31 December 2006 (2006-12-31), pages 173 - 181, XP005595254, DOI: doi:10.1016/j.ddstr.2006.06.012 * |
GABRIELLA CSEKE ET AL: "Human Metapneumovirus Fusion Protein Vaccines That Are Immunogenic and Protective in Cotton Rats", 《JOURNAL OF VIROLOGY》, vol. 81, no. 2, 18 October 2006 (2006-10-18), pages 698 - 707, XP002604579, DOI: doi:10.1128/JVI.00844-06 * |
HSIEN-SHENG YIN ET AL: "Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation", 《NATURE》, vol. 439, no. 5, 31 January 2006 (2006-01-31), pages 38 - 44, XP002600415, DOI: doi:10.1038/NATURE04322 * |
HSIEN-SHENG YIN ET AL: "Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein", 《PNAS》, vol. 102, no. 26, 28 June 2005 (2005-06-28), pages 9288 - 9293, XP002503489, DOI: doi:10.1073/PNAS.0503989102 * |
M. EWASYSHYN ET AL: "Comparative analysis of the immunostimulatory properties of different adjuvants on the immunogenicity of a prototype parainfluenza virus type 3 subunit vaccine", 《VACCINE》, vol. 10, no. 6, 31 December 1992 (1992-12-31), pages 412 - 420, XP023710784, DOI: doi:10.1016/0264-410X(92)90072-R * |
NANCY D. ULBRANDT ET AL: "Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus", 《JOURNAL OF GENERAL VIROLOGY》, vol. 89, 31 December 2008 (2008-12-31), pages 3113 - 3118, XP002604581, DOI: doi:10.1099/VIR.0.2008/005199-0 * |
PHILIP R. DORMITZER ET AL: "Structure-based antigen design: a strategy for next generation vaccines", 《TRENDS IN BIOTECHNOLOGY》, vol. 26, no. 12, 31 December 2008 (2008-12-31), pages 659 - 667, XP025645865, DOI: doi:10.1016/j.tibtech.2008.08.002 * |
SANDER HERFST ET AL: "Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains", 《JOURNAL OF GENERAL VIROLOGY》, 31 December 2007 (2007-12-31), pages 2702 - 2709 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102743750A (zh) * | 2012-07-09 | 2012-10-24 | 江苏省农业科学院 | 一种复方免疫增强剂、禽用疫苗及其制备方法 |
CN102743750B (zh) * | 2012-07-09 | 2013-11-20 | 江苏省农业科学院 | 一种复方免疫增强剂、禽用疫苗及其制备方法 |
CN105188748A (zh) * | 2013-04-08 | 2015-12-23 | 米迪缪尼有限公司 | 疫苗组合物及使用方法 |
CN105693829A (zh) * | 2016-04-14 | 2016-06-22 | 青岛易邦生物工程有限公司 | 一种b型禽偏肺病毒f蛋白 |
CN105693829B (zh) * | 2016-04-14 | 2022-03-15 | 青岛易邦生物工程有限公司 | 一种b型禽偏肺病毒f蛋白 |
CN106119287A (zh) * | 2016-08-29 | 2016-11-16 | 广东华南联合疫苗开发院有限公司 | 一种表达呼吸道合胞病毒f蛋白的重组载体及方法 |
WO2018095330A1 (zh) * | 2016-11-22 | 2018-05-31 | 黄立民 | 重组rsv抗原 |
Also Published As
Publication number | Publication date |
---|---|
JP5796011B2 (ja) | 2015-10-21 |
WO2010149743A2 (en) | 2010-12-29 |
KR20120093811A (ko) | 2012-08-23 |
US8889146B2 (en) | 2014-11-18 |
JP2012530761A (ja) | 2012-12-06 |
IL217008A0 (en) | 2012-02-29 |
EP2445527A2 (en) | 2012-05-02 |
ZA201109164B (en) | 2012-09-26 |
CA2766205A1 (en) | 2010-12-29 |
EA201270062A1 (ru) | 2013-02-28 |
US20120135028A1 (en) | 2012-05-31 |
SG176807A1 (en) | 2012-01-30 |
MX2012000036A (es) | 2012-02-28 |
WO2010149743A3 (en) | 2011-03-10 |
AU2010264686A1 (en) | 2012-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102548578A (zh) | 疫苗 | |
CN102481359B (zh) | 重组rsv抗原 | |
US8563002B2 (en) | Recombinant RSV antigens | |
US20100203071A1 (en) | Chimeric antigens | |
US20110177117A1 (en) | Chimeric respiratory syncytial virus polypeptide antigens | |
US20160122398A1 (en) | Recombinant rsv antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1172276 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: SMITHKLINE BEECHAM BIOLOG Free format text: FORMER OWNER: ID BIOMEDICAL CORP. OF QUEBEC Effective date: 20150324 Free format text: FORMER OWNER: SMITHKLINE BEECHAM BIOLOG Effective date: 20150324 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150324 Address after: Belgium richling Texas Applicant after: Glaxo Smithkline Biologicals S.A. Address before: Quebec Applicant before: Id Biomedical Corp Quebec Applicant before: Glaxo Smithkline Biologicals S.A. |
|
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20170315 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1172276 Country of ref document: HK |